Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

The Third Way: Managing risk and retaining control for comme...

Karen Fraser of Quintiles discusses the opportunities presented to small- to mid-sized biotech companies by partnering with commercial outsourcing providers. For any biotech or pharmaceutical company with development-stage assets but limited or no commercial infrastructure, maximizing...

Articles

Time to forget in-house R&D: enter the fully outsourced drug...

Julia Skripka-Serry discusses pharma’s introduction of the fully outsourced drug discovery model, to coincide with our partnerships & licensing focus month. Fifty years ago, in-house R&D must have seemed like a great idea. Therapeutic targets flowed like wine, innovation was...

Articles

Executive perspectives: David-Alexandre Gros

External analysts are continually proposing new strategic directions for pharma, so pharmaphorum caught up with a David-Alexandre Gros, from Sanofi’s leadership team, to hear his vision from th

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital